Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
Role and principlesAssessment and patient selectionBaseline assessmentInterventionsMedicines and treatment safetyTargets, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Avoiding long-term benzodiazepine dependence

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Benzodiazepine toxicity or severe withdrawal

Reduced consciousness or breathing after benzodiazepines, especially with opioids or alcohol, and withdrawal with seizure, delirium, psychosis, severe autonomic disturbance or dangerous agitation requires emergency medical treatment.

Action: Use ABCDE, airway support, observations and bedside glucose, identify the exact agents, doses, timing and co-ingestants, and contact emergency toxicology or acute medical services. Protect from injury and do not continue an unsupervised abrupt withdrawal after physiological dependence.

Role and principles

Prevent avoidable long-term benzodiazepine exposure, distinguish dependence from addiction and relapse, recognise overdose and dangerous withdrawal, and plan collaborative individual tapering without abrupt cessation or blame.

Prevention begins before the first tablet. Establish whether anxiety is severe, disabling and genuinely requires short-lived symptomatic relief after non-pharmacological and disorder-specific treatments have been discussed. Explain sedation, falls, memory and driving impairment, respiratory danger with alcohol, opioids and other sedatives, and the risks of tolerance, dependence, addiction and withdrawal. Record the dose, maximum duration, target, dispensing plan, review date and how treatment will end. A crisis prescription should not silently convert into automatic repeat medication.

Guideline context is restrictive. NICE advises benzodiazepines only as a short-term crisis measure in GAD, says they should not be prescribed for panic disorder because long-term outcome is poorer, and advises against drug treatment to prevent PTSD. Lorazepam SmPCs license short-term adult use for severe disabling anxiety for two to four weeks only, at 1 to 4 mg daily in divided doses, under close supervision and at the lowest effective dose. Product details, age, organ function and co-medication determine any actual prescription.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Long-term taper principle

A patient has taken prescribed lorazepam daily for two years and wants to stop, but previously developed severe symptoms after abrupt cessation. Which plan best follows NICE NG215?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG215 dependence and withdrawal recommendationsShared prescribing decisions, dependence, slow proportional tapering, switching and withdrawal response.
  • MHRA benzodiazepine dependence warning updateJanuary 2026 strengthened warnings, end strategies, monitoring and tailored tapering.
  • Lorazepam tablets summary of product characteristicsLicensed severe-anxiety indication, adult dose, short duration and safety cautions.
  • NICE CG113 GAD and panic disorder recommendationsCrisis-only GAD use and recommendation against benzodiazepines for panic disorder.
  • NICE NG116 PTSD recommendationsRecommendation not to use drug treatments, including benzodiazepines, to prevent PTSD.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting review

Dependence is an expected physiological adaptation and can occur without compulsive drug-seeking. Addiction involves impaired control, craving or continued use despite harm, although the two can coexist. Tolerance may appear as reduced effect and pressure for dose escalation. Explore what each dose now does, missed-dose symptoms, timing, extra supplies, alcohol and drugs, sleep, falls, cognition and function. Use neutral language and acknowledge that prescribing decisions may once have reflected accepted practice; blame makes disclosure and safe withdrawal less likely.

NICE NG215 advises against abrupt cessation except exceptional medical circumstances. Agree a slow stepwise reduction proportionate to the current dose so decrements become smaller near the end, with regular review and patient influence over pace. Long duration, high dose, previous withdrawal, concurrent medicines and current support shape timing. A longer-half-life switch can be considered for a short-half-life benzodiazepine, but is not automatic. New, rapid or unusually intense symptoms after reduction suggest withdrawal; pause, make a smaller reduction or return to the previous tolerated dose while reassessing.

Key points

  • Before prescribing, discuss non-drug options, define the severe short-term indication, use the lowest effective dose for the shortest duration and agree the reduction or end strategy.
  • Lorazepam product information restricts anxiety use to severe disabling distress for two to four weeks only and gives 1 to 4 mg daily in divided doses for adults.
  • NICE advises no benzodiazepine for panic disorder and only a short-term crisis measure for GAD; do not use benzodiazepines to prevent PTSD.
  • Physical dependence can occur at therapeutic doses and is not identical to addiction; discuss tolerance, withdrawal and loss of control without stigmatising the person.
  • Do not stop abruptly except in exceptional medical circumstances; reduce slowly in steps proportionate to the current dose, making decrements smaller as the dose becomes lower.
  • Make the taper flexible: agree review intervals, pause or reduce the next decrement when withdrawal is intolerable, and consider returning to the previous tolerated dose.
  • For a short-half-life benzodiazepine, NICE says consider a switch to a longer-half-life agent, but individual contraindications, interactions and uncertain conversion require careful clinical planning.

Assessment and patient selection

Physiological dependence

Withdrawal symptoms emerge after reduction because the nervous system has adapted, even when every dose was taken exactly as prescribed.

Tolerance

The same dose produces less perceived relief or the person feels a higher dose is needed to obtain the former effect.

Addiction pattern

Craving, impaired control, unsanctioned escalation or continued use despite harm extends beyond physical dependence alone.

Withdrawal syndrome

Rapid-onset anxiety, insomnia, tremor, sensory change or unfamiliar symptoms after reduction may progress to seizure or delirium when severe.

Cumulative medicine harm

Sedation, memory difficulty, falls, driving impairment and respiratory suppression may become more clinically important than short-lived relief.

Red flags requiring action

  • Shallow breathing, cyanosis, reduced consciousness, aspiration or collapse after benzodiazepine exposure is especially dangerous with opioids, alcohol or other sedatives.
  • Seizure, delirium, hallucinations, psychosis, severe tremor or autonomic instability after a rapid dose reduction suggests complicated withdrawal and requires urgent care.
  • Escalating dose, early refill requests, multiple prescribers, craving or use for intoxication may indicate problems associated with dependence or addiction and needs non-judgmental assessment.

Baseline assessment

  1. 01
    Complete benzodiazepine historyFirst step
    Why
    Record agent, formulation, daily pattern, duration, indication, missed doses, extra use and previous withdrawal.
    Interpretation and limitations
    Actual exposure and half-life shape risk; repeat lists and prescription records may not reveal stockpiling, variable use or outside supply.
  2. 02
    Co-sedative and substance review
    Why
    Identify opioids, alcohol, Z-drugs, gabapentinoids, sedating antihistamines and illicit substances.
    Interpretation and limitations
    Combined respiratory, cognitive and falls risk can make the same benzodiazepine dose far more dangerous and influence which medicine is reduced first.
  3. 03
    Dependence and addiction assessment
    Why
    Explore tolerance, craving, control, dose escalation, function, harm and goals using neutral language.
    Interpretation and limitations
    Physical dependence alone does not establish addiction; the formulation determines whether routine tapering or specialist addiction support is required.
  4. 04
    Physical and mental safety review
    Why
    Assess respiration, falls, cognition, driving, pregnancy, mood, suicide risk and the original anxiety disorder.
    Interpretation and limitations
    Immediate toxicity or dangerous withdrawal overrides routine planning, while untreated underlying illness needs parallel evidence-based care.

Interventions

01Safe initiationMake the first prescription self-limitingFirst stepA benzodiazepine is being considered for a licensed severe short-term anxiety indication or a guideline-recognised crisis.+
  1. 1Discuss effective non-drug and disorder-specific options and check respiratory, falls, pregnancy, substance, opioid, driving and safeguarding risks.
  2. 2Agree the lowest effective product-specific dose, shortest duration, limited quantity, target symptom, review date and reduction or stop strategy before prescribing.
  3. 3Provide verbal and written dependence and withdrawal information and remove automatic repeats so continuation requires explicit benefit-harm review.
02Long-term reviewUnderstand use before reducingA person is taking a benzodiazepine beyond the planned short course or experiencing cumulative harm.+
  1. 1Reconstruct actual daily exposure, original indication, current benefit, dependence, addiction features, co-sedatives, previous tapers and the person's priorities.

Medicines and treatment safety

A time-limited symptomatic option for severe disabling anxiety, not routine long-term treatment and not a substitute for disorder-specific psychological or antidepressant care.

Lorazepam oral for severe short-term anxiety

For the licensed adult indication, give a total of 1 mg to 4 mg by mouth daily in divided doses for short-term use of two to four weeks only, at the lowest effective dose and under close supervision.

Agree the ending strategy before initiation; avoid alcohol and review opioids and other sedatives, respiratory disease, sleep apnoea, frailty, falls, hepatic impairment, pregnancy, driving, memory effects, dependence, addiction and withdrawal.

Targets, monitoring and follow-up

  • At every prescription review, record actual daily use, benefit against the original target, sedation, cognition, falls, driving and continued indication.
  • Ask about opioids, alcohol, Z-drugs, gabapentinoids and other sedatives because combined exposure changes respiratory and overdose risk.
  • Watch for tolerance, early refill requests, dose escalation, craving, loss of control and use for reasons beyond the agreed indication without assigning blame.
  • During tapering, review after agreed decrements and document withdrawal timing, sleep, original symptoms, mood, suicide risk, function and patient preference about pace.
  • If a taper cannot proceed, avoid further escalation, record the reason for temporary continuation, reduce current harms and set a date to reconsider reduction.

Special situations

Dependence is not misconduct

Physiological adaptation can occur during correct therapeutic use, and respectful explanation improves the chance of accurate disclosure and safe reduction.

The last steps may be hardest

Proportionate reductions naturally become smaller as dose falls, avoiding a final decrement that is large relative to the remaining exposure.

Withdrawal has a fingerprint

Fast onset after a missed dose, unfamiliar sensory symptoms and greater intensity than the original anxiety favour withdrawal over simple relapse.

Conversion is not arithmetic only

Equivalence estimates are imprecise and a longer-half-life drug can accumulate, so age, liver function and interactions matter before switching.

A pause is not failure

Holding a dose while intolerable symptoms settle can preserve trust and make later gradual reduction more achievable than forced progression.

Common pitfalls

  1. 01

    Issuing a crisis supply without a maximum duration, limited quantity, review date and end strategy.

  2. 02

    Calling every physically dependent patient addicted or interpreting withdrawal distress as manipulation.

  3. 03

    Stopping suddenly after long-term use and exposing the person to severe anxiety, seizure, delirium or psychosis.

  4. 04

    Using a fixed large decrement to zero despite NICE advice that reductions become smaller at lower doses.

  5. 05

    Switching automatically to diazepam without checking equivalence uncertainty, accumulation, hepatic function and individual preference.

  6. 06

    Treating benzodiazepine withdrawal with another medicine that also carries dependence and withdrawal risk.

JurisdictionUnited Kingdom
  • Falls, confusion, ataxia, driving impairment, memory problems or inability to care safely for dependants may make continued exposure immediately harmful.
  • Pregnancy, frailty, respiratory disease, sleep apnoea, hepatic impairment and concurrent opioids materially change the risk and require product-specific review.
    • 05
    Withdrawal-versus-relapse timeline
    Why
    Relate each new symptom to dose, interval, missed tablets and the pre-treatment syndrome.
    Interpretation and limitations
    Rapid onset, unfamiliar symptoms or greater-than-previous intensity favours withdrawal, though new illness and relapse still require clinical assessment.
  • 2Offer active treatment for the underlying anxiety or sleep problem and agree whether the initial goal is complete withdrawal or a safer stable reduction.
  • 3Choose timing, formulation and review frequency collaboratively, arranging specialist addiction, pharmacy or mental-health support when complexity or risk requires.
    • 03Individual taperReduce slowly and responsivelyThe person and prescriber are ready to reduce a physiologically established benzodiazepine regimen.+
    1. 1Use slow stepwise decrements proportionate to the current dose, make reductions smaller toward the end and record the flexible schedule and contact route.
    2. 2Review after reductions for withdrawal, relapse, falls, sleep, alcohol, mood and function and pause or make the next decrement smaller if symptoms are intolerable.
    3. 3Consider a longer-half-life switch for a short-half-life drug only after checking conversion uncertainty and individual contraindications, and continue underlying-condition care.